Healthcare Industry News:  benign prostatic hyperplasia 

Devices Urology

 News Release - May 16, 2008

Urologix Launches New CTC Advance Catheter at 2008 American Urological Association Annual Meeting

MINNEAPOLIS--(HSMN NewsFeed)--Urologix®, Inc. (NASDAQ:ULGX ) announced today it is launching its next generation Cooled ThermoTherapy™ (CTT) treatment catheter, CTC Advance™ at the 2008 American Urological Association Annual Meeting in Orlando, Florida being held May 17-22, 2008. Urologix is the pioneer of Cooled ThermoTherapy for the treatment of enlarged prostate disease in the comfortable setting of a physician’s office.

The CTC Advance microwave catheter is the latest advancement in Cooled ThermoTherapy, a customizable and durable nonsurgical treatment for enlarged prostate disease, also known as benign prostatic hyperplasia (BPH). The CTC Advance is the next step in the evolution of the Company's treatment catheters. It builds on the proven safety, efficacy and durability of the Urologix CTC catheter by improving flexibility and increasing the cooled surface area proximal to the treatment area.

"The CTC Advance catheter is another improvement in cooled microwave thermotherapy. It is easier to insert and the additional cooling helps further preserve healthy urethral tissue. It demonstrates Urologix' commitment to quality patient care and is another reason why I use their microwave technology exclusively," said Dr. Robert Pugach, Medical Director at Pacific Coast Urology.

The CTC Advance catheter works with both the Urologix CoolWave® and Targis® control units. As compared to our current CTC microwave catheter, CTC Advance is 72% more flexible in the treatment area and provides 50% more cooled surface area proximal to the treatment area. The CTC Advance microwave catheter has been used to treat patients in the US during a pre-launch period since FDA approval on March 31, 2008. Physician feedback during the pre-launch patient treatments confirmed the improvements of CTC Advance.

"The launch of CTC Advance represents Urologix’ commitment to continuous improvement of our technology. CTC Advance is the latest generation of Cooled ThermoTherapy which is a proven alternative for the treatment of Enlarged Prostate Disease that offers meaningful benefits to patients, physicians and payors as compared to other treatment alternatives. The American Urological Association’s annual meeting is an outstanding venue for our company to introduce the CTC Advance microwave catheter to the Urologic community," stated Mitchell Dann, Chairman and Interim CEO of Urologix.

About Urologix

Urologix, Inc., based in Minneapolis, develops, manufactures and markets minimally invasive medical products for the treatment of urological disorders. The Company has developed and offers non-surgical, anesthesia-free, catheter-based treatments that use a proprietary cooled microwave technology for the treatment of benign prostatic hyperplasia (BPH), a condition that affects more than 23 million men worldwide. Urologix’ products include the CoolWave®, Targis® and Prostatron® control units and the Cooled ThermoCath®, Targis® and Prostaprobe® catheter families. All of Urologix’ products utilize Cooled ThermoTherapy™ a proprietary combination of microwave energy and cooling to protect healthy tissue and enhance patient comfort - and provide safe, effective, lasting relief of the symptoms of BPH.

Forward Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate” or “continue” or comparable terminology are intended to identify forward-looking statements. These statements are subject to certain risks and uncertainties that could cause the actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include the risk factors and other cautionary statements described in the Company’s Annual Report on Form 10-K for the year ended June 30, 2007 and other documents filed with the Securities and Exchange Commission.

Source: Urologix

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.